January 29, 2017
Cyrus Biotechnology supports the Boston Area Group for Informatics and Modeling
SEATTLE and BOSTON, January 10, 2017 — Cyrus Biotechnology, Inc., a new biotechnology software company offering the most advanced protein modeling and design capabilities to the Biopharmaceutical, Synthetic Biology, Chemical, and Consumer Products industries is pleased to support the Boston Area Group for Informatics and Modeling (BAGIM).
With over 700 members and 17 industrial sponsors, BAGIM is one of the most preeminent and active professional communities in the Boston area, focusing on computer based modeling, facilitating information exchange and networking through presentations of scientific relevance by luminaries from industry and academia. In 2016, BAGIM has hosted nine well attended scientific presentations and networking events and continues to maintain an active presence on social media such as LinkedIn, Meetup, and Facebook.
In silico modeling and design of proteins is becoming increasingly relevant to the pharmaceutical industry, as investment in research, development and clinical trials of biologic therapeutics continue to grow. Cyrus Bench software, and the underlying Rosetta software package, are already leveraged by many global pharmaceutical organizations and are at the nexus of this major trend. Cyrus customers can apply the most advanced and validated in silico protein engineering science through an intuitive user interface for:
- Protein Structure Prediction (best overall performance at CASP and CAMEO)
- Protein Stabilization (single point mutants, multiple point mutants, evolutionary redesign)
- Protein / Protein Interface Design
- Protein Design (modifications to function or structure)
- Enzyme Optimization
Cyrus is pleased to support BAGIM ‘s efforts to advance biological informatics and modeling. Sponsorship from Cyrus will contribute to BAGIM expenses related to its educational/networking initiative centered around a lecture series.
BAGIM (Boston Area Group for Informatics and Modeling)
BAGIM is an active community of Boston area scientists bringing together people from diverse fields of modeling and informatics to impact life and health sciences. BAGIM strives to create a forum for great scientific discussions covering a wide range of topics including data management, visualization, computational chemistry, drug discovery, protein structure, molecular modeling, structure-based drug design, data mining, software tools, and the sharing of goals and experiences. Our community is made up of participants from academia, government, and/or industry whose goal is to engage in the discussion of science involving a synthesis of theory and technology. Discussions sponsored by BAGIM are targeted to the needs and interests of informatics scientists, computational chemists, medicinal chemists, and statisticians. BAGIM also provides opportunities for networking within these disciplines as well as an arena for the dissemination of information of specific interest to the membership.
Cyrus Biotechnology, Inc. is a new privately-held biotechnology software company offering protein modeling and design capabilities to the Biopharmaceutical, Chemical, Consumer Products and Synthetic Biology industries. Cyrus was founded in 2014 as a spin-out from the University of Washington, and offers Bench, a Software-as-a-Service (SaaS) platform for protein structure prediction, modeling, stabilization, engineering and design to accelerate discovery of Biologics and Small Molecules. Cyrus Bench is based primarily on the Rosetta software package from Prof. David Baker’s lab at the University of Washington, along with associated software. Cyrus Bench offers the world-leading protein structure prediction pipeline of Rosetta and SparksX, the top structure prediction software in the bi-annual CASP competition and the weekly CAMEO competition, as well as the only protein engineering software experimentally proven to design new proteins completely via software. Cyrus Bench is based on over 15 years of biochemistry software development and over 400 published papers demonstrating experimental efficacy in vitro and in vivo.